Enliven Therapeutics, Inc. $ELVN Shares Purchased by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 61.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 211,752 shares of the company’s stock after buying an additional 80,506 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.43% of Enliven Therapeutics worth $4,167,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ameriprise Financial Inc. acquired a new stake in Enliven Therapeutics in the 4th quarter valued at about $789,000. Rhumbline Advisers raised its holdings in shares of Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock worth $1,033,000 after purchasing an additional 2,466 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Enliven Therapeutics by 67.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock valued at $984,000 after buying an additional 17,546 shares during the period. Millennium Management LLC grew its stake in Enliven Therapeutics by 108.6% during the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company’s stock valued at $1,143,000 after purchasing an additional 26,449 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $112,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ELVN shares. Robert W. Baird boosted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research report on Monday, June 16th. HC Wainwright boosted their target price on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, July 2nd. Finally, The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research report on Monday, June 16th. They set a “buy” rating and a $37.00 target price on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $41.20.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $20.63, for a total value of $67,047.50. Following the completion of the sale, the chief financial officer owned 23,000 shares in the company, valued at approximately $474,490. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Samuel Kintz sold 10,393 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $20.02, for a total transaction of $208,067.86. Following the transaction, the chief executive officer directly owned 929,999 shares of the company’s stock, valued at $18,618,579.98. This represents a 1.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,734 shares of company stock worth $1,908,314. Corporate insiders own 25.90% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $19.02 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The business’s fifty day moving average is $20.23 and its 200-day moving average is $19.67. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -9.51 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.